About Us

Publications

BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.

 

Found 9 results
Filters: Keyword is Myelodysplastic Syndromes  [Clear All Filters]
2021
R. Nakamura, Saber, W., Martens, M. J., Ramirez, A., Scott, B., Oran, B., Leifer, E., Tamari, R., Mishra, A., Maziarz, R. T., McGuirk, J., Westervelt, P., Vasu, S., Patnaik, M., Kamble, R., Forman, S. J., Sekeres, M. A., Appelbaum, F., Mendizabal, A., Logan, B., Horowitz, M., and Cutler, C., “Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.”, J Clin Oncol, vol. 39, no. 30, pp. 3328-3339, 2021.
B. L. Scott, Pasquini, M. C., Fei, M., Fraser, R., Wu, J., Devine, S. M., Porter, D. L., Maziarz, R. T., Warlick, E., Fernandez, H. F., Soiffer, R. J., Alyea, E., Hamadani, M., Bashey, A., Giralt, S., Geller, N. L., Leifer, E., Hourigan, C. S., Gui, G., Mendizabal, A., Horowitz, M. M., H Deeg, J., and Horwitz, M. E., “Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.”, Transplant Cell Ther, vol. 27, no. 6, pp. 483.e1-483.e6, 2021.
2017
B. L. Scott, Pasquini, M. C., Logan, B. R., Wu, J., Devine, S. M., Porter, D. L., Maziarz, R. T., Warlick, E. D., Fernandez, H. F., Alyea, E. P., Hamadani, M., Bashey, A., Giralt, S., Geller, N. L., Leifer, E., Le-Rademacher, J., Mendizabal, A. M., Horowitz, M. M., H Deeg, J., and Horwitz, M. E., “Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.”, J Clin Oncol, vol. 35, no. 11, pp. 1154-1161, 2017.
M. Abu Zaid, Wu, J., Wu, C., Logan, B. R., Yu, J., Cutler, C., Antin, J. H., Paczesny, S., and Choi, S. Won, “Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.”, Blood, vol. 129, no. 2, pp. 162-170, 2017.
2016
P. V. O'Donnell, Eapen, M., Horowitz, M. M., Logan, B. R., DiGilio, A., Brunstein, C., Fuchs, E. J., Flowers, M. E. D., Salit, R., Raj, K., Pagliuca, A., Bradstock, K., Granata, A., Castagna, L., Furst, S., and Blaise, D., “Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis.”, Bone Marrow Transplant, vol. 51, no. 12, pp. 1599-1601, 2016.
2015
F. R. Appelbaum, Anasetti, C., Antin, J. H., Atkins, H., Davies, S., Devine, S., Giralt, S., Heslop, H., Laport, G., Lee, S. J., Logan, B., Pasquini, M., Pulsipher, M., Stadtmauer, E., Wingard, J. R., and Horowitz, M. M., “Blood and marrow transplant clinical trials network state of the Science Symposium 2014.”, Biol Blood Marrow Transplant, vol. 21, no. 2, pp. 202-24, 2015.
2014
E. K. Waller, Logan, B. R., Harris, W. A. C., Devine, S. M., Porter, D. L., Mineishi, S., McCarty, J. M., Gonzalez, C. E., Spitzer, T. R., Krijanovski, O. I., Linenberger, M. L., Woolfrey, A., Howard, A., Wu, J., Confer, D. L., and Anasetti, C., “Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201.”, J Clin Oncol, vol. 32, no. 22, pp. 2365-72, 2014.
W. Saber, Le Rademacher, J., Sekeres, M., Logan, B., Lewis, M., Mendizabal, A., Leifer, E., Appelbaum, F. R., Horowitz, M. M., Nakamura, R., and Cutler, C. S., “Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and M”, Biol Blood Marrow Transplant, vol. 20, no. 10, pp. 1566-72, 2014.
E. Atallah, Bylow, K., Troy, J., and Saber, W., “Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT).”, Curr Hematol Malig Rep, vol. 9, no. 1, pp. 57-65, 2014.